[go: up one dir, main page]

WO2005046661A3 - Use of nitric oxide donors for the treatment of drug addiction - Google Patents

Use of nitric oxide donors for the treatment of drug addiction Download PDF

Info

Publication number
WO2005046661A3
WO2005046661A3 PCT/GB2004/004666 GB2004004666W WO2005046661A3 WO 2005046661 A3 WO2005046661 A3 WO 2005046661A3 GB 2004004666 W GB2004004666 W GB 2004004666W WO 2005046661 A3 WO2005046661 A3 WO 2005046661A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitric oxide
treatment
drug addiction
oxide donors
donors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/004666
Other languages
French (fr)
Other versions
WO2005046661A2 (en
Inventor
Eric Arthur Germai Demoncheaux
Wilfred Winston Yeo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield filed Critical University of Sheffield
Publication of WO2005046661A2 publication Critical patent/WO2005046661A2/en
Publication of WO2005046661A3 publication Critical patent/WO2005046661A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the use of a nitric oxide donor compound in the manufacture of a medicament for treating a drug addiction disorder.
PCT/GB2004/004666 2003-11-07 2004-11-05 Use of nitric oxide donors for the treatment of drug addiction Ceased WO2005046661A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326047.8 2003-11-07
GBGB0326047.8A GB0326047D0 (en) 2003-11-07 2003-11-07 Substance

Publications (2)

Publication Number Publication Date
WO2005046661A2 WO2005046661A2 (en) 2005-05-26
WO2005046661A3 true WO2005046661A3 (en) 2005-08-18

Family

ID=29726156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004666 Ceased WO2005046661A2 (en) 2003-11-07 2004-11-05 Use of nitric oxide donors for the treatment of drug addiction

Country Status (2)

Country Link
GB (1) GB0326047D0 (en)
WO (1) WO2005046661A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084911A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Improved device for application of medicaments, manufacturing method therefor, and method of treatment
WO2006084912A1 (en) 2005-02-11 2006-08-17 Nolabs Ab Device method, and use for treatment of neuropathy involving nitric oxide
ATE429255T1 (en) 2005-03-24 2009-05-15 Nolabs Ab COSMETIC TREATMENT WITH NITROGEN OXIDE, DEVICE FOR PERFORMING SUCH TREATMENT AND PRODUCTION METHOD THEREOF
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
AU2012203798B2 (en) * 2005-08-12 2013-11-07 Northrop Grumman Systems Corporation O-nitro compounds, pharmaceutical compositons thereof and uses thereof
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US8980871B2 (en) * 2007-09-20 2015-03-17 Wake Forest University Health Sciences Methods of treatment for hemolysis
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
CN102008473B (en) * 2010-11-23 2014-12-17 中国人民解放军第二军医大学 Application of nicotine and medical composition
EP2645860A4 (en) * 2010-12-03 2014-07-09 Geno Llc NITRIC OXIDE TREATMENTS
BR112014000178A2 (en) 2011-07-05 2017-02-07 Novan Inc topical compositions
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
JP6019126B2 (en) 2011-10-07 2016-11-02 エピセントアーレックス・インコーポレイテッドＥｐｉｃｅｎｔＲｘ， Ｉｎｃ． Organic nitrothioether compounds and their medical applications
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
ES2836132T3 (en) 2013-08-08 2021-06-24 Novan Inc Topical compositions and methods of using them
EP3177262A4 (en) 2014-08-08 2018-04-18 Novan Inc. Topical emulsions
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
PL3402480T3 (en) 2016-01-11 2021-11-22 Epicentrx, Inc. COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1- (3,3-DINITROAZETIDIN-1-YLO) ETHANONE
KR102319497B1 (en) 2016-03-02 2021-11-01 노반, 인크. Composition for treating inflammation and method for treating inflammation
KR20220050236A (en) 2016-04-13 2022-04-22 노반, 인크. Compositions, Systems, Kits and Methods for Treating an Infection
CN110352190A (en) 2016-10-14 2019-10-18 埃皮辛特瑞柯斯公司 Sulphur oxygroup alkyl Organic nitro and related compound and pharmaceutical composition for medical application
IL311727A (en) 2017-07-07 2024-05-01 Epicentrx Inc Compositions for parenteral administration of therapeutic agents
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092633A1 (en) * 2001-11-13 2003-05-15 Stamler Jonathan S. Preventing desensitization of receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092633A1 (en) * 2001-11-13 2003-05-15 Stamler Jonathan S. Preventing desensitization of receptors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ADAMS M L, SEWING B N, CHEN J, MEYER E R, CICERO T J: "Nitric oxide-related agents alter alcohol withdrawal in male rats", ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, vol. 19, no. 1, 1995, pages 195 - 199, XP008044769 *
BOHN M J: "ALCOHOLISM", PSYCHIATRIC CLINICS OF NORTH AMERICA, XX, XX, vol. 16, no. 4, 1 December 1993 (1993-12-01), pages 679 - 692, XP000562131 *
PEACHEY J E ET AL: "THE ROLE OF DRUGS IN THE TREATMENT OF ALCOHOLISM", DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 27, no. 2, February 1984 (1984-02-01), pages 171 - 182, XP009019053, ISSN: 0012-6667 *
PEACHEY J E, ANNIS H M, BORNSTEIN E R, SYKORA K, MAGLANA S M, SHAMAI S: "Calcium carbimide in alcoholism treatment. Part 1: a placebo-controlled, double-blind clinical trial of short-term efficacy", BRITISH JOURNAL OF ADDICTION, vol. 84, no. 8, 1989, pages 877 - 887, XP008044765 *
ZMEILI S, SALHAB A, SHUBAIR K, GHARAIBEH M, SULIMAN N, AL-KAYED A, SHUBAIR M, ABU HIJLEH N, ABU JBARA M: "Clinical evaluation of a new A.S. mouth wash 881010 as an antismoking agent: a placebo-controlled double-blind trial", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 37, no. 1, January 1999 (1999-01-01), pages 41 - 50, XP008044770 *

Also Published As

Publication number Publication date
WO2005046661A2 (en) 2005-05-26
GB0326047D0 (en) 2003-12-10

Similar Documents

Publication Publication Date Title
WO2005046661A3 (en) Use of nitric oxide donors for the treatment of drug addiction
WO2006060507A3 (en) Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2005096990A3 (en) Novel modification of medical prostheses
WO2007100675A3 (en) Collagenase for treating cellulite
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
ZA200407813B (en) Medicament for preventing and/or treating chronic rejection.
WO2007146426A3 (en) Nanoshells for drug delivery
WO2008128740A8 (en) Titration of tapentadol
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
WO2006119884A3 (en) Method for the treatment of drug abuse with flibanserin
WO2006039663A3 (en) Methods for the administration of iloperidone
WO2006099541A3 (en) Therapeutic wound care product
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2004050115A3 (en) Combination treatment using exendin-4 and thiazolidinediones
ZA200506422B (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
WO2006047631A3 (en) Anti-mitotic anti-proliferative compounds
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
WO2004103267A3 (en) Methods to administer epothilone d
WO2007100590A3 (en) Methods for treating cellulite
WO2004087880A8 (en) Compounds and their use to treat diabetes and related disorders
WO2006009874A3 (en) Methods and compositions for treatment of excess nitric oxide or cyanide toxicity
IL184697A (en) Injectable preparation containing diclofenic, a process for its preparation and use of the preparation in the manufacture of medication for the relief of pain and/or inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase